<DOC>
	<DOCNO>NCT02174419</DOCNO>
	<brief_summary>The primary objective study evaluate effect two dos nalbuphine HCl ER tablet change baseline bad itch Numerical Rating Scale ( NRS ) patient prurigo nodularis evaluate safety tolerability study population .</brief_summary>
	<brief_title>Study Nalbuphine HCl ER Tablets Patients With Prurigo Nodularis</brief_title>
	<detailed_description />
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Prurigo</mesh_term>
	<mesh_term>Neurodermatitis</mesh_term>
	<mesh_term>Nalbuphine</mesh_term>
	<criteria>Subject suffer generalized prurigo nodularis Have demonstrate pruritus intensity screen Male female least 18 year old time consent Subject chronic pruritus result condition Subject history substance abuse within past year Subject know drug allergy opioids Subject pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Itch</keyword>
	<keyword>Chronic Itch</keyword>
	<keyword>nalbuphine</keyword>
</DOC>